Cytokinetics Company Profile

Description

Cytokinetics, Incorporated, a late stage biopharmaceutical company, focuses on the discovery and development of novel small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions. It is developing tirasemtiv, a fast skeletal muscle troponin activator that is in Phase III clinical trials for the treatment of amyotrophic lateral sclerosis; CK-2127107, which is in Phase II clinical trials for the treatment of spinal muscle atrophy; and omecamtiv mecarbil, a novel cardiac muscle myosin activator that is in Phase II clinical trials for the treatment of heart failure. The company has strategic alliances with Amgen Inc. to discover, develop, and commercialize novel small molecule therapeutics that activate cardiac muscle contractility for applications in the treatment of heart failure; and Astellas Pharma Inc. to advance novel therapies for diseases and medical conditions associated with muscle weakness. Cytokinetics, Incorporated has a research collaboration with Origent Data Sciences to refine and validate a computer model to predict the course of ALS disease progression. The company was founded in 1997 and is headquartered in South San Francisco, California.